Pemphigus Vulgaris – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pemphigus Vulgaris – Pipeline Review, H2 2016’, provides an overview of the Pemphigus Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris

The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects

The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Almirall, S.A.

Biogen Inc

HanAll Biopharma Co., Ltd.

Immunomedics, Inc.

Novartis AG

Principia Biopharma Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pemphigus Vulgaris Overview 6

Therapeutics Development 7

Pipeline Products for Pemphigus Vulgaris - Overview 7

Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8

Pemphigus Vulgaris - Therapeutics under Development by Companies 9

Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10

Pemphigus Vulgaris - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Pemphigus Vulgaris - Products under Development by Companies 15

Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16

Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17

Almirall, S.A. 17

Biogen Inc 18

HanAll Biopharma Co., Ltd. 19

Immunomedics, Inc. 20

Novartis AG 21

Principia Biopharma Inc. 22

Pemphigus Vulgaris - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

ADP-31415 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

DPC-006 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

HL-161 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

PRN-1008 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

rituximab - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

VAY-736 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

veltuzumab - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Pemphigus Vulgaris - Dormant Projects 50

Pemphigus Vulgaris - Discontinued Products 51

Pemphigus Vulgaris - Product Development Milestones 52

Featured News & Press Releases 52

Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 52

Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 52

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H2 2016 7

Number of Products under Development for Pemphigus Vulgaris – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Pemphigus Vulgaris – Pipeline by Almirall, S.A., H2 2016 17

Pemphigus Vulgaris – Pipeline by Biogen Inc, H2 2016 18

Pemphigus Vulgaris – Pipeline by HanAll Biopharma Co., Ltd., H2 2016 19

Pemphigus Vulgaris – Pipeline by Immunomedics, Inc., H2 2016 20

Pemphigus Vulgaris – Pipeline by Novartis AG, H2 2016 21

Pemphigus Vulgaris – Pipeline by Principia Biopharma Inc., H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Pemphigus Vulgaris – Dormant Projects, H2 2016 50

Pemphigus Vulgaris – Discontinued Products, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H2 2016 7

Number of Products under Development for Pemphigus Vulgaris – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Top 10 Mechanism of Actions, H2 2016 26

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports